scPharmaceuticals Reclassified to Neutral from Buy by H.C. Wainwright
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 29 2025
0mins
Acquisition Details
- Downgrade by H.C. Wainwright: H.C. Wainwright has downgraded scPharmaceuticals (SCPH) from a Buy rating to Neutral.
- New Price Target: The price target for SCPH has been reduced to $5.35 from a previous target of $18.
Financial Implications
- Acquisition by MannKind: scPharmaceuticals has agreed to be acquired by MannKind (MNKD) at a price of $5.35 per share in cash.
- Contingent Value Rights: In addition to the cash payment, shareholders will receive one non-tradable contingent value right per share, which could yield milestone payments totaling up to $1.00.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
